Drug Trial Radar · NCT05421923
The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jun 24, 2022
Primary completion
Oct 5, 2022
Study completion Oct 5, 2022
Sponsor
- Lead sponsor
- Shanghai SIMR Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, PD, safety and tolerability of SR1375 in healthy subjects.
Conditions
- Healthy
Interventions
SR1375 capsulesDrug
Ascending single and multiple doses of SR1375 orally
PlaceboOther
Ascending single and multiple doses of Placebo orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: On scheduled intervals from Day 1 up to Day 54
- TmaxTime frame: On scheduled intervals from Day 1 up to Day 54
- AUCTime frame: On scheduled intervals from Day 1 up to Day 54
- CL/FTime frame: On scheduled intervals from Day 1 up to Day 54
- t1/2Time frame: On scheduled intervals from Day 1 up to Day 54
- RacTime frame: On scheduled intervals from Day 1 up to Day 54
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Phase I clinical laboratory of Huashan Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.